Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Assets (2016 - 2025)

Historic Return on Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 0.47%.

  • Ultragenyx Pharmaceutical's Return on Assets fell 1100.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year decrease of 1100.0%. This contributed to the annual value of 0.38% for FY2024, which is 200.0% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Return on Assets of 0.47% as of Q3 2025, which was down 1100.0% from 0.41% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Return on Assets registered a high of 0.12% during Q1 2021, and its lowest value of 0.54% during Q2 2023.
  • Its 5-year average for Return on Assets is 0.39%, with a median of 0.4% in 2024.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Return on Assets surged by 2400bps in 2021, and later plummeted by -2200bps in 2022.
  • Ultragenyx Pharmaceutical's Return on Assets (Quarter) stood at 0.3% in 2021, then tumbled by -48bps to 0.45% in 2022, then grew by 1bps to 0.44% in 2023, then grew by 16bps to 0.38% in 2024, then fell by -24bps to 0.47% in 2025.
  • Its Return on Assets stands at 0.47% for Q3 2025, versus 0.41% for Q2 2025 and 0.39% for Q1 2025.